Systematic (IUPAC) name | |
---|---|
gadolinium(+3) cation; 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy cat. | ? |
Legal status | ℞-only (US) |
Routes | IV |
Identifiers | |
CAS number | 120066-54-8 |
ATC code | V08CA04 |
PubChem | CID 60714 |
DrugBank | DB00597 |
ChemSpider | 54719 |
UNII | 0199MV609F |
KEGG | D01137 |
ChEBI | CHEBI:31643 |
ChEMBL | CHEMBL1200593 |
Synonyms | (10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium |
Chemical data | |
Formula | C17H29GdN4O7 |
Mol. mass | 558.68 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.